Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002371 · ClinicalTrials.gov registry record · Phase 3
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
A Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 8
- Study locations
NCT00002371 is a Phase 3 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 80 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT00002371, a Phase 3 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 8
- Study locations
Study Summary
To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Stavudine
Study Locations (8)
California
- Harbor UCLA Med Ctr - Torrance
Florida
- Univ of South Florida - Tampa
New York
- SUNY at Stony Brook / Division of Infectious Diseases - Stony Brook
Texas
- Houston Clinical Research Network / Div of Montrose Clinic - Houston
Utah
- Univ of Utah / School of Medicine / Div of Infect Dis - Salt Lake City
Ontario
- Sunnybrook Health Science Ctr - North York
Quebec
- Montreal Gen Hosp / Div of Clin Immuno and Allergy - Montreal
Other
- Univ of Puerto Rico School of Medicine - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1996-06 |
| Est. Completion | 1997-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002371
The ClinicalTrials.gov registry entry for NCT00002371 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (82% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Zidovudine is the first listed.
NCT00002371 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00002371 about?
NCT00002371 is a clinical study titled "The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine". To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.
What is the current status of trial NCT00002371?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 1996-06. Estimated completion is 1997-12.
What conditions does trial NCT00002371 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002371?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG), Stavudine (DRUG).
Who is sponsoring clinical trial NCT00002371?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002371 being conducted?
This trial has 8 study locations across California, Florida, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.